^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation. (PubMed, Front Immunol)
    An elderly male diagnosed with Stage IV LUAD achieved sustained stable disease (SD) and symptomatic improvement through a sequential therapeutic strategy, including platinum-based chemotherapy followed by the PD-1 inhibitor sintilimab combined with anti-angiogenic agents (apatinib or anlotinib). This case demonstrates that while ICIs can provide exceptional long-term benefits in advanced NSCLC, particularly in patients with highly immunogenic mutation profiles, they may also trigger late-onset fatal irAEs. Our findings underscore the imperative for close, long-term metabolic surveillance throughout the course of immunotherapy, regardless of treatment duration or radiological stability.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS G12C • KRAS G12
    |
    Focus V (anlotinib) • Tyvyt (sintilimab) • AiTan (rivoceranib)
    5d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    6d
    Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer (ChiCTR2600117016)
    P=N/A, N=80, Not yet recruiting, Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed • Cosela (trilaciclib)
    6d
    A Randomized, Controlled, Multicenter Phase Ⅲ Trial of Sintilimab as Consolidation Therapy in Unresectable ESCC Patients Without Disease Progression After Concurrent Taxane-Based Chemoradiotherapy (ChiCTR2500115299)
    P=N/A, N=258, Completed, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New trial
    |
    Tyvyt (sintilimab)
    6d
    Efficacy and Safety of Transarterial Chemoembolization Followed by Continuous Infusion Chemotherapy Combined with Bevacizumab Biosimilar and Sintilimab (the THBS Quadruple Regimen) for Unresectable Hepatocellular Carcinoma with High Tumor Burden: A Prospective Multicenter Exploratory Study (ChiCTR2500114805)
    P=N/A, N=63, Not yet recruiting, First Affiliated Hospital of the Army Medical University of the Chinese People's Liberation Army; First Affiliated Hospital of the Army Medical Univer
    New trial
    |
    Tyvyt (sintilimab)
    6d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced rectal cancer (ChiCTR2500114358)
    P=N/A, N=41, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    6d
    Efficacy and Safety of Multi-mode Thermal Therapy Combined with Paclitaxel plus Gemcitabine (AG Regimen) as First-Line Treatment for Pancreatic Cancer with Liver Metastases: A Prospective Single-Arm Study (ChiCTR2500111957)
    P=N/A, N=6, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
    New trial
    |
    gemcitabine • paclitaxel • Tyvyt (sintilimab)
    6d
    A Single-Arm, Single-Center, Prospective Phase II Clinical Study of Stephania Longa and Jiezai Rice Combined with Sintilimab in Advanced Driver Gene-Negative, PD-L1-Positive NSCLC Patients Who Failed First-Line Immunotherapy (ChiCTR2500114858)
    P=N/A, N=29, Recruiting, Hainan General Hospital; Hainan General Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • RET fusion • ALK fusion • ROS1 fusion
    |
    Tyvyt (sintilimab)
    6d
    Optimization of immunotherapy strategies for locally advanced and metastatic gastric cancer under the guidance of CTCs and ctDNA (ChiCTR2500113727)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • docetaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    Exploratory Clinical Study of Fruquintinib Combined with Sintilimab and Chemotherapy as Adjuvant Treatment for Stage III Gastric Cancer after Surgery (ChiCTR2500114651)
    P4, N=32, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New P4 trial
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    6d
    Prospective Study on Adjuvant Therapy After Resection for Ruptured Hepatocellular Carcinoma with Hemorrhage: A Prospective Exploratory Single-Arm Study of Adjuvant Sintilimab Combined with Bevacizumab (CLEAR-2 Study) (ChiCTR2500112474)
    P4, N=30, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P4 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab)
    6d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (ChiCTR2500114611)
    P4, N=38, Recruiting, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New P4 trial
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin